Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37586177/
Approximately 1-2% of advanced NSCLC harbor rare fusions, which are potentially actionable and may support diagnosis. Routine adoption of broad NGS assays capable to identify exact fusion points and potentially...
Conclusions: Approximately 1–2% of advanced NSCLC harbor rare fusions, which are potentially actionable and may support diagnosis. Routine adoption of broad NGS assays capable to identify exact fusion points and potentially retained protein domains can increase the yield of therapeutically relevant molecular information in advanced NSCLC.
Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial
Source : https://tlcr.amegroups.org/article/view/75390/html
Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial
Concusions/Relevance: For the field of thoracic oncology, this publication demonstrates the durable benefit of selpercatinib, and the clinical focus is on ensuring patients undergo the appropriate molecular testing for RET fusions and have access to RET TKIs. Academically the field is investigating the mechanisms of resistance, and these...
Resolving the role of podoplanin in the motility of papillary thyroid carcinoma-derived cells using RNA sequencing - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37560122/
The intracellular level of podoplanin (PDPN), a transmembrane protein of still unclear function, is frequently altered in metastatic tumors. High expression of PDPN is frequently observed in papillary thyroid cancer...
Conclusions/Relevance: We found that changes in the expression of various factors of signaling pathways, like RHOA and RAC1 GTPases and their regulators, are linked with both high PDPN levels and presence of the BRAF V600E mutation. We imply that the suppressed motility of wild-type BCPAP cells results from overactivation of RHOA through...
Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset
Source : https://www.sciencedirect.com/science/article/pii/S1936523323001304?via=ihub
RET fusions are driver alterations in cancer and are most commonly found in non-small cell lung cancer and well-differentiated thyroid cancer. However...
Conclusions: RET fusions were identified in multiple tumor types. With a higher median TMB and commonly MSI-H, RET fusion positive CRC may be a unique molecular subset of CRC.
A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring KIF5B-RET Fusion Responds to First-Line Pralsetinib Treatment: A Case Report
Presenting a case of metastatic PSC harboring de novo KIF5B-RET fusion, and the patient responded to first-line trametinib treatment. Read more
Conclusions/Relevance: Despite their effectiveness in RET fusion-positive NSCLC is observed, the efficacy of these inhibitors in PSC remains unclear. In this context, we present a case of metastatic PSC harboring de novo KIF5B-RET fusion. The patient responded to first-line trametinib treatment. These findings suggest that RET inhibitors...